|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Capitanio U, Bensalah K, Bex A, Boorjian
SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P:
Epidemiology of renal cell carcinoma. Eur Urol. 75:74–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Obeng RC, Arnold RS, Ogan K, Master VA,
Pattaras JG, Petros JA and Osunkoya AO: Molecular characteristics
and markers of advanced clear cell renal cell carcinoma: Pitfalls
due to intratumoral heterogeneity and identification of genetic
alterations associated with metastasis. Int J Urol. 27:790–797.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Downs TM, Schultzel M, Shi H, Sanders C,
Tahir Z and Sadler GR: Renal cell carcinoma: Risk assessment and
prognostic factors for newly diagnosed patients. Crit Rev Oncol
Hematol. 70:59–70. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Motzer RJ, Jonasch E, Agarwal N, Alva A,
Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh
IA, et al: Kidney cancer, version 3.2022, nccn clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 20:71–90. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li N, Kang Y, Wang L, Huff S, Tang R, Hui
H, Agrawal K, Gonzalez GM, Wang Y, Patel SP and Rana TM: ALKBH5
regulates anti-PD-1 therapy response by modulating lactate and
suppressive immune cell accumulation in tumor microenvironment.
Proc Natl Acad Sci USA. 117:20159–20170. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu H, Xu Z, Wang Z, Ren Z, Li L and Ruan
Y: Exosomes from dendritic cells with Mettl3 gene knockdown prevent
immune rejection in a mouse cardiac allograft model.
Immunogenetics. 72:423–430. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang L, Hui H, Agrawal K, Kang Y, Li N,
Tang R, Yuan J and Rana TM: m6A RNA methyltransferases
METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J.
39:e1045142020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu X, Wang P, Teng X, Zhang Z and Song S:
Comprehensive analysis of expression regulation for RNA m6A
regulators with clinical significance in human cancers. Front
Oncol. 11:6243952021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fang J, Hu M, Sun Y, Zhou S and Li H:
Expression profile analysis of m6A RNA methylation regulators
indicates they are immune signature associated and can predict
survival in kidney renal cell carcinoma. DNA Cell Biol.
39:2194–2211. 2020. View Article : Google Scholar
|
|
11
|
Wang J, Zhang C, He W and Gou X: Effect of
m6A RNA methylation regulators on malignant progression
and prognosis in renal clear cell carcinoma. Front Oncol. 10:32020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mayakonda A, Lin DC, Assenov Y, Plass C
and Koeffler HP: Maftools: Efficient and comprehensive analysis of
somatic variants in cancer. Genome Res. 28:1747–1756. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Robin X, Turck N, Hainard A, Tiberti N,
Lisacek F, Sanchez JC and Müller M: pROC: An open-source package
for R and S+ to analyze and compare ROC curves. BMC Bioinformatics.
12:772011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kassambara A, Kosinski M and Biecek P:
Survminer: Drawing survival curves using ‘ggplot2’. R package
version 0.4.9. 2021.https://CRAN.R-project.org/package=survminer
|
|
16
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C,
Sjöstedt E, Asplund A, et al: Tissue-based map of the human
proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Harrell FE Jr: Rms: Regression modeling
strategies. R package version 6.2-0. 2021.https://cran.r-project.org/web/packages/rms/index.html
|
|
18
|
Yoshihara K, Kim H and Verhaak RG:
Estimate: Estimate of stromal and immune cells in malignant tumor
tissues from expression data. R package version 1.0.13/r21.
2016.https://r-forge.r-project.org/projects/estimate/
|
|
19
|
Shen C, Xuan B, Yan T, Ma Y, Xu P, Tian X,
Zhang X, Cao Y, Ma D, Zhu X, et al: m6A-dependent
glycolysis enhances colorectal cancer progression. Mol Cancer.
19:722020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang T, Kong S, Tao M and Ju S: The
potential role of RNA N6-methyladenosine in cancer progression. Mol
Cancer. 19:882020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wojciechowski P, Lipowska A, Rys P, Ewens
KG, Franks S, Tan S, Lerchbaum E, Vcelak J, Attaoua R, Straczkowski
M, et al: Impact of FTO genotypes on BMI and weight in polycystic
ovary syndrome: A systematic review and meta-analysis.
Diabetologia. 55:2636–2645. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zarza-Rebollo JA, Molina E and Rivera M:
The role of the FTO gene in the relationship between depression and
obesity. A systematic review. Neurosci Biobehav Rev. 127:630–637.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qiu Y, Wang X, Fan Z, Zhan S, Jiang X and
Huang J: Integrated analysis on the N6-methyladenosine-related long
noncoding RNAs prognostic signature, immune checkpoints, and immune
cell infiltration in clear cell renal cell carcinoma. Immun Inflamm
Dis. 9:1596–1612. 2021. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu T, Gao S, Ruan H, Liu J, Liu Y, Liu D,
Tong J, Shi J, Yang H, Chen K and Zhang X: METTL14 Acts as a
potential regulator of tumor immune and progression in clear cell
renal cell carcinoma. Front Genet. 12:6091742021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mu Z, Dong D, Sun M, Li L, Wei N and Hu B:
Prognostic value of YTHDF2 in clear cell renal cell carcinoma.
Front Oncol. 10:15662020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lan Q, Liu PY, Haase J, Bell JL,
Hüttelmaier S and Liu T: The critical role of RNA m6A
methylation in cancer. Cancer Res. 79:1285–1292. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang C, Huang S, Zhuang H, Ruan S, Zhou
Z, Huang K, Ji F, Ma Z, Hou B and He X: YTHDF2 promotes the liver
cancer stem cell phenotype and cancer metastasis by regulating OCT4
expression via m6A RNA methylation. Oncogene. 39:4507–4518. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hou J, Zhang H, Liu J, Zhao Z, Wang J, Lu
Z, Hu B, Zhou J, Zhao Z, Feng M, et al: YTHDF2 reduction fuels
inflammation and vascular abnormalization in hepatocellular
carcinoma. Mol Cancer. 18:1632019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fang R, Chen X, Zhang S, Shi H, Ye Y, Shi
H, Zou Z, Li P, Guo Q, Ma L, et al: EGFR/SRC/ERK-stabilized YTHDF2
promotes cholesterol dysregulation and invasive growth of
glioblastoma. Nat Commun. 12:1772021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xie H, Li J, Ying Y, Yan H, Jin K, Ma X,
He L, Xu X, Liu B, Wang X, et al: METTL3/YTHDF2 m(6)A axis promotes
tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer.
J Cell Mol Med. 24:4092–4104. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Edens BM, Vissers C, Su J, Arumugam S, Xu
Z, Shi H, Miller N, Ringeling FR, Ming GL, He C and Song H: FMRP
modulates neural differentiation through m(6)a-dependent mRNA
nuclear export. Cell Rep. 28:845–854.e845. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hsu PJ, Shi H, Zhu AC, Lu Z, Miller N,
Edens BM, Ma YC and He C: The RNA-binding protein FMRP facilitates
the nuclear export of N6-methyladenosine-containing
mRNAs. J Biol Chem. 294:19889–19895. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang F, Kang Y, Wang M, Li Y, Xu T, Yang
W, Song H, Wu H, Shu Q and Jin P: Fragile X mental retardation
protein modulates the stability of its m6A-marked messenger RNA
targets. Hum Mol Genet. 27:3936–3950. 2018.PubMed/NCBI
|
|
34
|
Liu L, Wang Y, Wu J, Liu J, Qin Z and Fan
H: N 6-Methyladenosine: A potential breakthrough for
human cancer. Mol Ther Nucleic Acids. 19:804–813. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang H, Weng H, Zhou K, Wu T, Zhao BS,
Sun M, Chen Z, Deng X, Xiao G, Auer F, et al: Histone H3
trimethylation at lysine 36 guides m6A RNA modification
co-transcriptionally. Nature. 567:414–419. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang C, Chen L, Liu Y, Huang J, Liu A, Xu
Y, Shen Y, He H and Xu D: Downregulated METTL14 accumulates BPTF
that reinforces super-enhancers and distal lung metastasis via
glycolytic reprogramming in renal cell carcinoma. Theranostics.
11:3676–3693. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang F, Hu A, Li D, Wang J, Guo Y, Liu Y,
Li H, Chen Y, Wang X, Huang K, et al: Circ-HuR suppresses HuR
expression and gastric cancer progression by inhibiting CNBP
transactivation. Mol Cancer. 18:1582019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ronkainen H, Vaarala MH, Hirvikoski P and
Ristimäki A: HuR expression is a marker of poor prognosis in renal
cell carcinoma. Tumour Biol. 32:481–487. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Danilin S, Sourbier C, Thomas L, Rothhut
S, Lindner V, Helwig JJ, Jacqmin D, Lang H and Massfelder T: Von
hippel-lindau tumor suppressor gene-dependent mRNA stabilization of
the survival factor parathyroid hormone-related protein in human
renal cell carcinoma by the RNA-binding protein HuR.
Carcinogenesis. 30:387–396. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Danilin S, Sourbier C, Thomas L, Lindner
V, Rothhut S, Dormoy V, Helwig JJ, Jacqmin D, Lang H and Massfelder
T: Role of the RNA-binding protein HuR in human renal cell
carcinoma. Carcinogenesis. 31:1018–1026. 2010. View Article : Google Scholar : PubMed/NCBI
|
